美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

iShares Health Innovation Active ETF

33.32

+0.10420.31%

盤後：33.23-0.0850-0.26%16:10 EDT

成交量：583

成交額：1.94萬

市值：1,332.60萬

市盈率：- -

高：33.32

開：33.23

低：33.23

收：33.21

52周最高：34.86

52周最低：25.79

股本：40.00萬

流通股本：40.00萬

量比：0.29

換手率：0.15%

股息：0.08

股息率：0.24%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

康哲藥業：9月14日CMS-D001獲SLE臨床試驗批准

阿斯利康(AZN.US)乳腺癌藥物Etcamah三期臨床試驗受挫或致數十億美元銷售額蒙陰

阿斯利康(AZN.US)乳腺癌藥物Etcamah三期臨床試驗受挫或致數十億美元銷售額蒙陰

強生骨科業務引阿波羅興趣，潛在200億美元交易推動盤前股價上漲1.2%

強生股價盤前上漲1.2%，此前有報道稱阿波羅全球管理公司有意收購強生旗下骨科業務，潛在交易估值約為200億美元。

港股異動 | 科倫博泰生物(06990)升逾3% POLARIS-1臨床試驗2期部分取得陽性結果並已啓動3期臨床

長風藥業（02652）續漲3.76% ICF001拿到三項臨床試驗默示許可

強生Rybrevant聯合化療在EGFR外顯子20插入突變非小細胞肺癌中實現迄今報告最長的中位總生存期

強生：RYBREVANT聯合化療在EGFR外顯子20插入突變非小細胞肺癌中實現已報告的最長中位總生存期。

強生據報與阿波羅洽談約200億美元骨科業務交易

环球市场播报

傳阿波羅(APO.US)擬接盤強生(JNJ.US)骨科業務潛在交易估值近200億美元

據彭博社報導，阿波羅全球正就收購強生公司骨科業務部門進行談判

據彭博社報道，阿波羅全球正就收購強生公司骨科業務部門進行談判

據稱阿波羅正在洽談收購強生骨科業務部門。

美國食品藥品監督管理局（FDA）批准了Scholar Rock公司的一款治療肌肉無力症的藥物

阿斯利康：SERENA-4臨床試驗未達到主要終點。

美國股市動態

興齊眼藥(300573.SZ)：SQ-23082滴眼液獲批開展臨床試驗

興齊眼藥：SQ-23082獲臨床試驗批准，屬2.1類

強生（JNJ）漲1.63% 新款雙周拋隱形眼鏡獲CE認證

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/BMED/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BMED","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","market":"US","secType":"STK","nameCN":"iShares Health Innovation Active ETF","latestPrice":33.315,"timestamp":1789502400000,"preClose":33.2108,"halted":0,"volume":583,"hourTrading":{"tag":"盘后","latestPrice":33.23,"preClose":33.315,"latestTime":"16:10 EDT","volume":6,"amount":199.89,"timestamp":1789503006991,"change":-0.085,"changeRate":-0.002551,"amplitude":0},"delay":0,"changeRate":0.0031375335734158388,"floatShares":400000,"shares":400000,"eps":0,"marketStatus":"未開盤","change":0.1042,"latestTime":"09-15 16:00:00 EDT","open":33.23,"high":33.315,"low":33.23,"amount":19399,"amplitude":0.002559,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789545600000},"marketStatusCode":0,"adr":0,"exchange":"ARCA","adjPreClose":33.2108,"sharesOutstanding":360000,"nav":33.210436,"aum":13284174.4,"dividendRate":0.002392,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":33.23,"preClose":33.315,"latestTime":"16:10 EDT","volume":6,"amount":199.89,"timestamp":1789503006991,"change":-0.085,"changeRate":-0.002551,"amplitude":0},"volumeRatio":0.294683,"impliedVol":0.0634,"impliedVolPercentile":0.004},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","floatShares":400000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.294683,"shares":400000,"dividePrice":0.0797,"high":33.315,"amplitude":0.002559,"preClose":33.2108,"low":33.23,"week52Low":25.794,"pbRate":"--","week52High":34.86,"institutionHeld":0,"latestPrice":33.315,"eps":0,"divideRate":0.002392,"volume":583,"delay":0,"ttmEps":0,"open":33.23,"prevYearClose":30.32,"prevWeekClose":32.965,"prevMonthClose":33.8091,"prevQuarterClose":30.62,"fiveDayClose":33.33,"twentyDayClose":32.4416,"sixtyDayClose":28.4203},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BMED\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"BMED","amount":0.08118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Health Innovation Active ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2023-12-20","symbol":"BMED","amount":0.007207,"announcedDate":"2023-12-20","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"BlackRock Future Health ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BMED\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.007207,"currency":"USD"},{"executeDate":"2026-06-15","recordDate":"2026-06-15","paymentDate":"2026-06-18","value":0.08118,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BMED\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BMED\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667657480","title":"康哲藥業：9月14日CMS-D001獲SLE臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667657480","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667657480?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 18:23","pubTimestamp":1789381383,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4077","IBBJ","BMED","SLE","MDTX","PSYK","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667599986","title":"阿斯利康(AZN.US)乳腺癌藥物Etcamah三期臨床試驗受挫 或致數十億美元銷售額蒙陰","url":"https://stock-news.laohu8.com/highlight/detail?id=2667599986","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667599986?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:27","pubTimestamp":1789374476,"startTime":"0","endTime":"0","summary":"Bloomberg Intelligence分析师John Murphy表示，阿斯利康此次乳腺癌药物试验受挫可能使2035年的销售额减少26亿至38亿美元。ESR1突变是ER阳性乳腺癌内分泌治疗耐药的重要机制。CAMBRIA-1比较Etcamah延长辅助治疗5年 vs 标准内分泌治疗，中高复发风险。如果CAMBRIA阳性，Etcamah的市场空间将远大于晚期ESR1突变人群——这也是阿斯利康对Etcamah 50亿美元峰值销售额预期的核心支撑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495608.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBJ","PSYK","BMED","IBBQ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667599576","title":"阿斯利康(AZN.US)乳腺癌藥物Etcamah三期臨床試驗受挫 或致數十億美元銷售額蒙陰","url":"https://stock-news.laohu8.com/highlight/detail?id=2667599576","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667599576?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:27","pubTimestamp":1789374476,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","MDTX","IBBJ","BMED","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171745492","title":"強生骨科業務引阿波羅興趣，潛在200億美元交易推動盤前股價上漲1.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=1171745492","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171745492?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:18","pubTimestamp":1789373891,"startTime":"0","endTime":"0","summary":"据报道，强生公司的骨科业务部门吸引了阿波罗全球管理的关注，这一潜在交易估值或达200亿美元。受此消息提振，强生股价在盘前交易中上涨了1.2%。知情人士透露，私募股权巨头阿波罗已就收购强生骨科业务的可能性进行了初步接触。强生骨科业务涵盖创伤修复、关节置换、脊柱外科及运动医学等多个细分领域，在全球范围内拥有广泛的市场布局。截至发稿时，强生和阿波罗均未对此传闻发表官方评论。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","BK4588","LU1551013342.USD","IE00BLSP4452.SGD","LU1066053197.SGD","IE00B775SV38.USD","LU1043141123.HKD","LU1914381329.SGD","BK4568","AAUM","LU2133065610.SGD","IE00BFTCPJ56.SGD","LU0345770308.USD","LU2592432038.USD","BMED","LU0069063385.USD","LU2750360997.AUD","LU0162691827.USD","IE0001KFT4U8.USD","LU2417539215.USD","LU2750360641.GBP","LU0795875169.SGD","LU1061106388.HKD","LU0106831901.USD","LU1674673428.USD","LU1244550221.USD","LU1228905037.USD","LU0787776722.HKD","LU1244550577.SGD","SG9999013999.USD","IE00BLSP4239.USD","IE00BVYPNV92.GBP","LU0234572021.USD","LU2236285917.USD","LU1430594728.SGD","SG9999001440.SGD","LBO","IE00B3PB1722.GBP","LU1221951129.SGD","IE000WAW04H5.SGD","LU1221951046.USD","LU1496350502.SGD","LU0122379950.USD","LU0210536198.USD","GPZ","BK4559","LU1059921491.USD","LU2213496289.HKD","LU1066051498.USD","LU0792757196.USD","IE00B19Z3B42.SGD","LU0889566641.SGD","FHLC","IE000F7OJYX1.SGD","LU0057025933.USD","LU1162221912.USD","LU2129689605.HKD","LU1718418525.SGD","IE0034235303.USD","LU0432979614.USD","LU0472753341.HKD","LU0114720955.EUR","IE00BFXG1179.USD","IE0000B7K699.USD","LU2430703095.HKD","LU0289961442.SGD","LU0289739699.SGD","LU2023250330.USD","IE000MB6IJN5.SGD","BK4550","IE00B3S45H60.SGD","BK4581","IE00BJT1NW94.SGD","LU2505996681.GBP","XLV","LU0683600562.USD","LU1057294990.SGD","LU1043141396.HKD","IE00BSNM7G36.USD","LU1506573853.SGD","LU2347655156.SGD","BK4135","LU0234570918.USD","LU1023059063.AUD","LU0511384066.AUD","IE00B19Z3581.USD","IHE","IE00B2B36J28.USD","LU2505996509.AUD","LU2602419157.SGD","LU0203347892.USD","LU1894683264.USD","LU1074936037.SGD","IE00B1BXHZ80.USD","IXJ","LU1066051811.HKD","LU1585245621.USD","LU1196500208.SGD","LU1267930813.SGD","LU0098860793.USD","JNJ","LU1280957306.USD","MEDX","SG9999001176.USD","LU0882574055.USD","LU1935042991.SGD","LU0466842654.USD","LU1791807156.HKD","LU1551013425.SGD","SG9999002224.SGD","LU1989771016.USD","IE00BBT3K403.USD","LU2129689431.USD","IE000M9KFDE8.USD","LU0070217475.USD","LU2129689514.USD","PRVT","LU0345770993.USD","LU2471134879.HKD","LU0289739343.SGD","LU0345769128.USD","LU0006061336.USD","LU0820561909.HKD","BK4585","LU1629891620.HKD","IE0002270589.USD","IE00BN8TJ469.HKD","LU0210528500.USD","LU0345769631.USD","LU1674673691.USD","BK4532","IE00B3T34201.USD","LU0124676726.USD","LU0820562030.AUD","LU0912757837.SGD","LU1778281490.HKD","APO","LU2487616109.SGD","SG9999002232.USD","LU2112291526.USD","LU2456880835.USD","BK4504","LU0964807845.USD","LU0689626769.HKD","IE00BZ1G4Q59.USD","LU2403377893.USD","LU2471134952.CNY","LU0689472784.USD","IE0009355771.USD","LU0203345920.USD","LU2471134796.USD","IE000SO60NU8.SGD","IE00BGHQF631.EUR","BK4184","LU1228905540.USD","LU1032955483.USD","LU0943347566.SGD","JDOC","PJP","LU1261432733.SGD","FTXH","LU0320765646.SGD","LU1732800096.USD","LU0426417589.USD","IE00B42XCP33.USD","LU1032466523.USD","IYH","LU2089984988.USD","SG9999001176.SGD","BK4592","IE00B4R5TH58.HKD","IE000BZT7R73.USD","LU0053666078.USD","LU0058720904.USD","IE00B7SZLL34.SGD","LU0994945656.USD","LU2471134523.USD","SGXZ57979304.SGD","LU2756315318.SGD","LU0640476718.USD","SGXZ80539844.SGD","RXL","LU1929549753.HKD","LU0545562505.USD","LU1894683348.USD","IE00BJJMRZ35.SGD","IE00BDGV0183.EUR","LU1066051225.USD","BK4007","LU0072461881.USD","LU0426412945.USD","LU2430703251.USD","TRUH","BK4534","LU1983299246.USD","LU2896262040.SGD","IE00BVYPNW00.USD","LU2430703178.SGD","LU1291159041.SGD","LU1732799900.SGD","LU1668664300.SGD","GDOC","LU1244550494.USD","IE0002141913.USD","LU0985320562.USD","LU1145028129.USD","LU0795875086.SGD","LU0820561818.USD","LU2468319806.SGD","VHT","LU1121112475.USD","LU2756315664.SGD","LU1323610961.USD","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667659843","title":"強生股價盤前上漲1.2%，此前有報道稱阿波羅全球管理公司有意收購強生旗下骨科業務，潛在交易估值約為200億美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667659843","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667659843?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:18","pubTimestamp":1789373891,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["RXL","VHT","LU1430594728.SGD","IE00B42XCP33.USD","IE000BZT7R73.USD","LU2430703251.USD","LU0320765646.SGD","PJP","IE00BDGV0183.EUR","AAUM","IE00BKVL7J92.USD","BMED","FTXH","TRUH","LU1244550221.USD","IE000WAW04H5.SGD","LU1221951046.USD","LU2023250330.USD","BK4184","BK4585","IE00BN8TJ469.HKD","LU1585245621.USD","LU1066051225.USD","LU0882574055.USD","LU0345769128.USD","LU0889566641.SGD","MEDX","GPZ","LU0426412945.USD","LU1032466523.USD","IXJ","LBO","IYH","IHE","LU1267930813.SGD","JNJ","LU1066053197.SGD","LU0289739343.SGD","IE0009355771.USD","JDOC","GDOC","LU2592432038.USD","PRVT","XLV","LU2896262040.SGD","LU0792757196.USD","APO","LU0070217475.USD","FHLC","BK4559"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667658010","title":"港股異動 | 科倫博泰生物(06990)升逾3% POLARIS-1臨床試驗2期部分取得陽性結果 並已啓動3期臨床","url":"https://stock-news.laohu8.com/highlight/detail?id=2667658010","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667658010?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 14:36","pubTimestamp":1789367775,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物涨超3%，截至发稿，涨3.35%，报480.8港元，成交额2.53亿港元。消息面上，近日，科伦博泰生物发布公告，公司的合作方Windward Bio AG已公布SKB378/WIN378用于治疗哮喘的POLARIS-1临床试验2期部分取得阳性的中期结果。POLARIS-1的3期部分已由Windward Bio启动，确定采用两种每年两次给药的剂量方案，旨在评估SKB378/WIN378对重度哮喘患者的年化哮喘急性发作率及其他关键疗效指标的影响。POLARIS-1的2期研究数据将在即将召开的医学会议上公布。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495550.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","MDTX","BK1161","BK4588","LU0196878994.USD","PSYK","IBBQ","KCAI","VXUS","IBBJ","BMED","06990"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667631770","title":"長風藥業（02652）續漲3.76% ICF001拿到三項臨床試驗默示許可","url":"https://stock-news.laohu8.com/highlight/detail?id=2667631770","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667631770?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 10:16","pubTimestamp":1789352216,"startTime":"0","endTime":"0","summary":"金吾财讯 | 长风药业（02652）股价扬升，续涨3.76%，报10.75港元，成交额3166万港元。消息面上，长风药业自研创新药长效吸入粉雾剂ICF001接连拿到三项临床试验默示许可。截至目前，这款候选药物已覆盖PAH、PH-ILD、IPF、PPF四大适应症，也是国内首家将该类长效吸入前药推进至国内临床试验阶段的企业。公司董事长兼执行董事梁文青博士称，将同步开展海内外I期临床，积极布局海外合作开发、区域授权等全球化商业化路径。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991472","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","IBBJ","02652","PSYK","MDTX","BMED","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120093998","title":"強生Rybrevant聯合化療在EGFR外顯子20插入突變非小細胞肺癌中實現迄今報告最長的中位總生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1120093998","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120093998?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 09:47","pubTimestamp":1789350464,"startTime":"0","endTime":"0","summary":"强生公司日前公布了一项重磅临床数据——其旗下药物Rybrevant与化疗联用，在携带EGFR外显子20插入突变的非小细胞肺癌患者中，取得了目前公开报告中最长的中位总生存期。EGFR外显子20插入突变，历来被视为治疗难点，可选方案有限且疗效欠佳。观察人士指出，这不仅能巩固Rybrevant在精准医疗版图中的地位，更可能重塑晚期非小细胞肺癌的一线治疗格局。强生能否借此在竞争激烈的肺癌药物市场中进一步扩大优势，值得持续跟踪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZLL34.SGD","IE00BZ1G4Q59.USD","LU0114720955.EUR","LU0426412945.USD","BK4581","LU1059921491.USD","LU1074936037.SGD","LU1066053197.SGD","LU2896262040.SGD","IE000MB6IJN5.SGD","LU0787776722.HKD","LU0820561818.USD","LU0320765646.SGD","LU2505996509.AUD","LU0289961442.SGD","LU0203347892.USD","IE000M9KFDE8.USD","LU1228905037.USD","LU2089984988.USD","LU2430703095.HKD","LU0795875169.SGD","LU1430594728.SGD","LU2430703178.SGD","LU0210536198.USD","LU0943347566.SGD","LU2417539215.USD","LU0053666078.USD","IE00BVYPNV92.GBP","LU1551013425.SGD","LU2129689431.USD","LU1674673428.USD","IE00BN8TJ469.HKD","IE00BSNM7G36.USD","LU1066051225.USD","SGXZ80539844.SGD","LU2430703251.USD","LU0124676726.USD","BK4559","LU1196500208.SGD","LU0426417589.USD","LU0795875086.SGD","LU1778281490.HKD","LU0070217475.USD","LU2505996681.GBP","LU2129689514.USD","LU1221951129.SGD","LU2602419157.SGD","SGXZ57979304.SGD","LU2487616109.SGD","IE0002270589.USD","IE00BFTCPJ56.SGD","LU2756315664.SGD","BK4585","LU1585245621.USD","LU2471134796.USD","JDOC","LU2347655156.SGD","IE0000B7K699.USD","IE00B4R5TH58.HKD","LU2750360641.GBP","TRUH","LU1244550221.USD","RXL","LU0162691827.USD","LU0820562030.AUD","LU1244550494.USD","LU0345770308.USD","LU1043141396.HKD","IE00BDGV0183.EUR","LU1894683264.USD","LU2023250330.USD","LU2592432038.USD","IE000F7OJYX1.SGD","LU1935042991.SGD","LU0889566641.SGD","BK4592","IE00B19Z3581.USD","IE00B2B36J28.USD","LU1629891620.HKD","LU0792757196.USD","IE0001KFT4U8.USD","LU1267930813.SGD","LU1914381329.SGD","IE00BGHQF631.EUR","BK4504","IE00BVYPNW00.USD","IE00BFXG1179.USD","LU1057294990.SGD","LU2133065610.SGD","SG9999013999.USD","LU0234570918.USD","LU1066051811.HKD","LU1983299246.USD","LU2213496289.HKD","LU1244550577.SGD","XLV","LU0985320562.USD","IE00BLSP4452.SGD","LU0432979614.USD","BK4588","BK4534","LU1732799900.SGD","IYH","LU1929549753.HKD","LU1023059063.AUD","IE0034235303.USD","IE0009355771.USD","LU1032955483.USD","LU1261432733.SGD","LU1718418525.SGD","IE00BJJMRZ35.SGD","LU0689472784.USD","LU1066051498.USD","LU0098860793.USD","LU1894683348.USD","IE000SO60NU8.SGD","BK4568","SG9999002224.SGD","LU1121112475.USD","JNJ","IE00B19Z3B42.SGD","LU1032466523.USD","BK4007","LU0234572021.USD","LU0994945656.USD","LU1732800096.USD","LU2403377893.USD","VHT","IE00B3T34201.USD","LU0345769128.USD","LU2756315318.SGD","SG9999001176.SGD","IE00B42XCP33.USD","LU2456880835.USD","IXJ","LU2471134523.USD","LU1043141123.HKD","BK4533","IE000WAW04H5.SGD","LU0057025933.USD","LU0820561909.HKD","LU2468319806.SGD","LU0203345920.USD","SG9999001176.USD","BMED","LU0345770993.USD","LU0964807845.USD","LU1280957306.USD","LU0058720904.USD","LU1674673691.USD","LU2236285917.USD","LU1506573853.SGD","LU2471134879.HKD","IE000BZT7R73.USD","LU0683600562.USD","LU1496350502.SGD","SG9999002232.USD","SG9999001440.SGD","LU1221951046.USD","PJP","IE00BKVL7J92.USD","LU1162221912.USD","LU0210528500.USD","IHE","LU2129689605.HKD","LU0345769631.USD","LU0289739699.SGD","LU0640476718.USD","BK4550","LU0069063385.USD","IE00B3PB1722.GBP","LU1551013342.USD","LU0882574055.USD","LU0466842654.USD","LU2750360997.AUD","IE00B1BXHZ80.USD","IE00BJT1NW94.SGD","LU1291159041.SGD","LU1989771016.USD","LU0689626769.HKD","LU0289739343.SGD","LU1061106388.HKD","LU1228905540.USD","LU0072461881.USD","FHLC","IE00BLSP4239.USD","LU2471134952.CNY","LU0912757837.SGD","GDOC","LU0511384066.AUD","FTXH","IE0002141913.USD","IE00BBT3K403.USD","LU0545562505.USD","MEDX","LU2112291526.USD","LU1145028129.USD","LU0472753341.HKD","BK4532","LU0122379950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667631840","title":"強生：RYBREVANT聯合化療在EGFR外顯子20插入突變非小細胞肺癌中實現已報告的最長中位總生存期。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667631840","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667631840?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 09:46","pubTimestamp":1789350398,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IE00BGHQF631.EUR","LU2471134523.USD","LU0053666078.USD","LU1145028129.USD","PJP","BK4588","FTXH","IE00BVYPNV92.GBP","LU2592432038.USD","GDOC","BK4568","IE0001KFT4U8.USD","BMED","LU0683600562.USD","VHT","IE0002141913.USD","LU2471134879.HKD","LU2133065610.SGD","LU0426417589.USD","LU0072461881.USD","IHE","BK4533","IE00B3T34201.USD","LU1280957306.USD","LU1674673691.USD","LU0820561909.HKD","IE00BLSP4239.USD","IYH","LU1032466523.USD","LU1935042991.SGD","MEDX","FHLC","IXJ","LU2430703095.HKD","TRUH","LU0511384066.AUD","LU1894683264.USD","XLV","JDOC","IE0000B7K699.USD","RXL","IE00BFTCPJ56.SGD","IE00BDGV0183.EUR","LU0985320562.USD","LU1244550494.USD","LU2089984988.USD","BK4550","LU0122379950.USD","BK4559","JNJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667329689","title":"強生據報與阿波羅洽談約200億美元骨科業務交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2667329689","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667329689?lang=zh_tw&edition=fundamental","pubTime":"2026-09-13 14:27","pubTimestamp":1789280820,"startTime":"0","endTime":"0","summary":"据知情人士消息，阿波罗全球管理公司正洽谈收购强生旗下以DePuy Synthes为主体的骨科业务，交易金额约为200亿美元。知情人士称，强生与阿波罗正在就出售展开谈判，但双方仍可能无法达成交易，强生也可能选择其他买家。强生和阿波罗目前均未公布交易安排。以当前报道的约200亿美元交易金额计算，潜在售价与强生当年的实际收购价格大致相当，但期间业务范围、财务表现和资产构成已经发生变化。此次潜在出售也是强生持续调整业务组合的一部分。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-09-13/doc-inirskha4546532.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["VHT","LU2456880835.USD","TRUH","LU1228905540.USD","LU2023250330.USD","IE000F7OJYX1.SGD","IYH","LU0122379950.USD","IE00B19Z3581.USD","LU1496350502.SGD","LU0889566641.SGD","LU0640476718.USD","PJP","IE0009355771.USD","LU0792757196.USD","LU0426412945.USD","BMED","LU1778281490.HKD","FTXH","IE00B42XCP33.USD","IE00B4R5TH58.HKD","JNJ","IE00BVYPNV92.GBP","LU2089984988.USD","LU0795875169.SGD","LU1066053197.SGD","LU1732800096.USD","LU2430703251.USD","LU1935042991.SGD","RXL","GDOC","IXJ","LU0689472784.USD","LU0795875086.SGD","LU0545562505.USD","XLV","IE00BFXG1179.USD","LU2896262040.SGD","IHE","LU1074936037.SGD","LU2471134523.USD","LU2129689431.USD","MEDX","LU1059921491.USD","LU1430594728.SGD","LU2213496289.HKD","JDOC","LU0057025933.USD","FHLC","LU0820561909.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666508051","title":"傳阿波羅(APO.US)擬接盤強生(JNJ.US)骨科業務 潛在交易估值近200億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666508051","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666508051?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 11:04","pubTimestamp":1789182275,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据媒体援引知情人士消息报道，全球另类资产管理公司阿波罗全球管理 正洽谈收购强生的骨科业务部门DePuy Synthes。这笔交易对该业务的估值可能接近200亿美元。强生的骨科业务部门DePuy Synthes主要生产关节植入物和手术器械，2025年创造了93亿美元的收入，但收入增速仅为1.1%。相比之下，强生2025年整体营收同比增长6%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495305.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["GPZ","JDOC","LU1057294990.SGD","LU1506573853.SGD","BK4585","IE00B3T34201.USD","BMED","LU2129689431.USD","VHT","LU0545562505.USD","LU0689626769.HKD","JNJ","IE00B42XCP33.USD","PRVT","LU2468319806.SGD","MEDX","AAUM","LBO","IHE","LU2487616109.SGD","LU0345769631.USD","LU0006061336.USD","LU2112291526.USD","FHLC","LU1244550494.USD","IXJ","LU2471134523.USD","APO","LU2756315318.SGD","LU2471134796.USD","FTXH","IE000F7OJYX1.SGD","LU2602419157.SGD","LU1989771016.USD","XLV","TRUH","GDOC","IE000BZT7R73.USD","PJP","IE00B775SV38.USD","LU0912757837.SGD","IYH","LU1162221912.USD","RXL","LU1267930813.SGD","LU1668664300.SGD","LU1032466523.USD","IE00BGHQF631.EUR","LU1066051498.USD","IE0001KFT4U8.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666778075","title":"據彭博社報導，阿波羅全球正就收購強生公司骨科業務部門進行談判","url":"https://stock-news.laohu8.com/highlight/detail?id=2666778075","media":"路透中文","labels":["corporation","merge","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666778075?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 06:42","pubTimestamp":1789166537,"startTime":"0","endTime":"0","summary":"据彭博社报导，阿波罗全球正就收购强生公司骨科业务部门进行谈判路透9月11日-据彭博社周五援引消息人士报导，阿波罗全球管理公司（Apollo Global Management，APO.N）正在就收购强生公司（Johnson & JohnsonJNJ.N）旗下骨科业务部门进行磋商，该交易可能使该业务部门的估值接近200亿美元。路透无法立即核实该报导。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nL4T4531JU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU1778281490.HKD","LU0795875086.SGD","IE00BGHQF631.EUR","LU2471134523.USD","LU2112291526.USD","LU0985320562.USD","LU0203347892.USD","IHE","LU1066051498.USD","RXL","JNJ","LBO","LU1585245621.USD","IXJ","LU0234572021.USD","LU1430594728.SGD","APO","FTXH","LU1228905540.USD","BK4592","IE00BVYPNW00.USD","JDOC","LU2347655156.SGD","PRVT","LU0345770993.USD","LU2487616109.SGD","LU0122379950.USD","BMED","IE00BSNM7G36.USD","BK4588","LU1551013342.USD","IYH","LU2129689514.USD","VHT","LU1668664300.SGD","LU2750360641.GBP","GPZ","LU1323610961.USD","GDOC","MEDX","FHLC","TRUH","LU1032955483.USD","LU1221951046.USD","PJP","LU1929549753.HKD","AAUM","LU0114720955.EUR","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666577802","title":"據彭博社報道，阿波羅全球正就收購強生公司骨科業務部門進行談判","url":"https://stock-news.laohu8.com/highlight/detail?id=2666577802","media":"路透中文","labels":["corporation","merge","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666577802?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 06:42","pubTimestamp":1789166537,"startTime":"0","endTime":"0","summary":"据彭博社报道，阿波罗全球正就收购强生公司骨科业务部门进行谈判路透9月11日-据彭博社周五援引消息人士报道，阿波罗全球管理公司（Apollo Global Management，APO.N）正在就收购强生公司（Johnson & JohnsonJNJ.N）旗下骨科业务部门进行磋商，该交易可能使该业务部门的估值接近200亿美元。路透无法立即核实该报道。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nL4S4531JU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FHLC","LU0820562030.AUD","LU0964807845.USD","LU1043141396.HKD","GDOC","MEDX","IYH","IXJ","JNJ","SG9999001176.USD","LU0234570918.USD","IE00BGHQF631.EUR","LU1935042991.SGD","LU2112291526.USD","LU1629891620.HKD","LU1506573853.SGD","LU1261432733.SGD","LU1894683264.USD","LU0882574055.USD","LU2756315664.SGD","IHE","LU1228905540.USD","APO","BK4504","BMED","IE000MB6IJN5.SGD","VHT","LU1221951129.SGD","LU2505996509.AUD","LU0203345920.USD","RXL","XLV","IE000M9KFDE8.USD","LU1989771016.USD","LBO","LU1196500208.SGD","TRUH","PRVT","BK4007","IE000F7OJYX1.SGD","IE00BFXG1179.USD","BK4585","JDOC","PJP","GPZ","IE00BKVL7J92.USD","LU0792757196.USD","FTXH","LU1059921491.USD","AAUM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666657206","title":"據稱阿波羅正在洽談收購強生骨科業務部門。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666657206","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666657206?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 06:25","pubTimestamp":1789165559,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SGXZ80539844.SGD","TRUH","LU2750360997.AUD","IE00BFXG1179.USD","IYH","LU0345770308.USD","IE0000B7K699.USD","LU0210536198.USD","LU0795875086.SGD","LU0943347566.SGD","FHLC","LU0964807845.USD","LU1221951046.USD","VHT","JDOC","SGXZ57979304.SGD","IE00B1BXHZ80.USD","IHE","LU0640476718.USD","LU2468319806.SGD","LU1057294990.SGD","LU0289739699.SGD","IE000SO60NU8.SGD","LU2756315664.SGD","XLV","IXJ","LU2487616109.SGD","LU1066051498.USD","LU0345770993.USD","LU2133065610.SGD","LU1244550221.USD","IE000WAW04H5.SGD","LU1732800096.USD","BMED","LU0689472784.USD","LU2213496289.HKD","LU0820562030.AUD","LU0985320562.USD","RXL","JNJ","GDOC","PJP","SG9999001440.SGD","MEDX","SG9999001176.USD","FTXH","IE00BGHQF631.EUR","IE00BZ1G4Q59.USD","LU0787776722.HKD","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666257258","title":"美國食品藥品監督管理局（FDA）批准了Scholar Rock公司的一款治療肌肉無力症的藥物","url":"https://stock-news.laohu8.com/highlight/detail?id=2666257258","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666257258?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 05:25","pubTimestamp":1789161915,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）批准了Scholar Rock公司的一款治疗肌肉无力症的药物路透9月11日-美国食品和药物管理局（FDA）周五批准了Scholar Rock公司开发的SRRK.O疗法，用于治疗一种会导致肌肉无力的罕见遗传性疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nL4T4531I4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","THNR","BMED","BIIB","BK4533","IE00B19Z9P08.USD","IBRN","BK4588","BK4139","LU0320765992.SGD","LU0889565916.HKD","SRRK","BK4585","IE00B19Z9Z06.USD","IE00B894F039.SGD","BK4532","LU0234570918.USD","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666457170","title":"阿斯利康：SERENA-4臨床試驗未達到主要終點。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666457170","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666457170?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 04:16","pubTimestamp":1789157801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","IBBJ","BMED","MDTX","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666576453","title":"美國股市動態","url":"https://stock-news.laohu8.com/highlight/detail?id=2666576453","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666576453?lang=zh_tw&edition=fundamental","pubTime":"2026-09-12 01:49","pubTimestamp":1789148968,"startTime":"0","endTime":"0","summary":".N美国东部时间13:30，道琼斯工业平均指数.DJI上涨1.15%，报52,664.99点。标普500指数.SPX上涨1.07%，报7,673.08点；纳斯达克综合指数.IXIC上涨1.21%，报26,397.44点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nL4S4531CA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GME","QQQG","HPE","RKLB","EW","ONB","RWT","EXEL","DLLL","AENT","ADBE","KBWB","CPRT","BDRX","ACVA","KR","PTF","ADBG","AGNG","RENT","OKLO","TNON","DELL","YARW","ORCL","FLR","PANW","TENB","RJF","CIBR","MRNA","FIZZ","SNDQ","WLDR","SORCLmain","IGV","SRFM","LHSW","STX","CNAV","PMTS","HPQ","UCAR","ATO","BMED","CHWY","OKLL","SNDK","IXG","SMR"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2666544063","title":"興齊眼藥(300573.SZ)：SQ-23082滴眼液獲批開展臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2666544063","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666544063?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 15:54","pubTimestamp":1789113276,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兴齐眼药(300573.SZ)发布公告，近日，公司收到国家药品监督管理局签发的关于SQ-23082滴眼液的《药物临床试验批准通知书》。SQ-23082滴眼液为公司研发的化学药品2.1类改良型新药。临床拟用于过敏性结膜炎相关的眼痒的治疗。根据改良型新药的有关要求，公司已经完成SQ-23082滴眼液药学及非临床药理毒理学等多方面的研究，研究结果表明SQ-23082滴眼液具有良好的安全性及临床开发价值。目前国内外尚无该眼用制剂产品上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494936.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IBBQ","BK0239","PSYK","IBBJ","BMED","300573","BK0177","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666226544","title":"興齊眼藥：SQ-23082獲臨床試驗批准，屬2.1類","url":"https://stock-news.laohu8.com/highlight/detail?id=2666226544","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666226544?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 15:47","pubTimestamp":1789112862,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","BMED","MDTX","PSYK","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666596063","title":"強生（JNJ）漲1.63% 新款雙周拋隱形眼鏡獲CE認證","url":"https://stock-news.laohu8.com/highlight/detail?id=2666596063","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666596063?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 21:21","pubTimestamp":1789046500,"startTime":"0","endTime":"0","summary":"金吾财讯 | 强生（JNJ）美股盘前股价震荡上行，最新涨1.63%，报271.4美元。消息面上，强生周四宣布，旗下新款ACUVUE OASYS MAX双周抛复用隐形眼镜已拿到CE认证。该款产品属于ACUVUE OASYS MAX产品线的新品，可在完整14天佩戴周期内保障佩戴舒适度与清晰视力。镜片搭载OptiBlue滤光技术、TearStable锁泪技术以及一类紫外线防护功能，专门面向长时间使用电子屏幕人群的用眼需求设计。上市节奏方面，计划2026年晚些时候率先登陆部分欧洲国家；后续视各地监管审批进度，在2027-2028年进一步拓展市场。目前该产品尚未取得美国FDA批准，暂未在美国市场销售。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/OGNjYWRkOTg0ZTNhODNlYjIwMzU4Nzc5OGE1MjIxNzAyOTY4ODU1OQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/OGNjYWRkOTg0ZTNhODNlYjIwMzU4Nzc5OGE1MjIxNzAyOTY4ODU1OQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305910","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","LU1228905037.USD","LU1244550494.USD","IE00BN8TJ469.HKD","IHE","FHLC","LU2750360997.AUD","TRUH","BK4532","LU0820562030.AUD","LU2756315318.SGD","LU2133065610.SGD","LU0124676726.USD","LU2456880835.USD","LU2505996509.AUD","RXL","LU0070217475.USD","BK4581","PJP","GDOC","LU1929549753.HKD","BMED","FTXH","BK4592","MEDX","LU1732800096.USD","LU0792757196.USD","LU1674673428.USD","LU0689626769.HKD","IE00BLSP4239.USD","IE00BGHQF631.EUR","LU0345770308.USD","LU0964807845.USD","IXJ","BK4559","LU1043141396.HKD","IE00BVYPNW00.USD","LU2750360641.GBP","IE000BZT7R73.USD","JNJ","LU1291159041.SGD","LU2756315664.SGD","VHT","LU1066053197.SGD","IE00BDGV0183.EUR","JDOC","IYH","LU0820561909.HKD","SG9999001440.SGD","LU0345770993.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}